Daré Bioscience, Inc.
DAREDaré Bioscience, Inc. in brief
Daré Bioscience, Inc. is a listed company in the Biotechnology industry, based in San Diego, California, USA. Its market value was $13 M on 28 October 2026, which makes it the 25,464th largest listed company in the world and the 4,240th largest in the USA on this site. In the year to December 2025 it had sales of $1 M and a net loss of $13 M. It employs about 24 people. Its largest product and service lines by sales in 2025 were License fee revenue and other revenue (100%). Its shares trade under the symbol DARE (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Daré Bioscience, Inc.
We are a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions. Every innovation we advance is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, pelvic pain to fertility, vaginal health to infectious disease, we’re working to close critical gaps in care using science that serves her needs.
For decades, women have been told to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline.
From the company's annual report filed with the US SEC: read the report
Daré Bioscience, Inc. timeline
- 2007
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2008
- ✎Renamed Cerulean Pharma Inc.Formerly Tempo Pharmaceuticals Inc.
- 2014
- 🔔Initial public offering as Cerulean Pharma Inc.Final prospectus filed with the SEC on 14 April 2014; shares registered for exchange trading on 4 April 2014.
- 2017
- ✎Renamed Dare Bioscience, Inc.Formerly Cerulean Pharma Inc..
Events of Daré Bioscience, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,505 (Dec 2022) · #4,563 (Jul 2023) · #4,206 (Jan 2024) · #2,301 (Mar 2026) · #3,998 (Aug 2026) · #4,220 (Oct 2026) · #4,242 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 12.6×
- Price / book
- 4.6×
- Free cash flow yield
- -79.2%
- Net margin
- -1301.0%
- Operating margin
- -1315.5%
- Return on equity
- -471.8%
- Liabilities / assets
- 91.3%
- Revenue growth
- +10200.0%
- R&D / revenue
- 535.9%
- Revenue per employee
- $43 K
- Profit per employee
- $-558 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1M | +10200.0% | $-14M | $-13M | -1301.0% |
| Dec 2024 | $0M | -99.6% | $-23M | $-4M | -40500.0% |
| Dec 2023 | $3M | -71.9% | $-31M | $-30M | -1073.3% |
| Dec 2022 | $10M | — | $-31M | $-31M | -309.5% |
| Dec 2021 | — | — | $-39M | $-39M | — |
| Dec 2020 | — | — | $-27M | $-27M | — |
| Dec 2019 | — | — | $-14M | $-14M | — |
| Dec 2018 | — | — | $-17M | $-17M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-10M | $0M | $-10M | $-1.20 | — |
| Dec 2024 | $5M | $1M | $5M | $-0.48 | — |
| Dec 2023 | $-39M | $1M | $-39M | $-4.15 | — |
| Dec 2022 | $-18M | $0M | $-18M | $-0.37 | — |
| Dec 2021 | $-29M | $0M | $-29M | $-0.63 | — |
| Dec 2020 | $-25M | $0M | $-25M | $-0.91 | — |
| Dec 2019 | $-13M | $0M | $-13M | $-0.97 | — |
| Dec 2018 | $-10M | $0M | $-10M | $-1.57 | — |
Quarterly results
Latest quarter to Jun 2026: revenue $0M, net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 12, 20268-KCurrent reportShareholder vote
- Oct 6, 2026DEF 14AProxy statement
- Oct 2, 20268-KCurrent reportListing notice
- Oct 1, 20268-KCurrent reportRegulation FD disclosure
- Sep 11, 20268-KCurrent reportBylaws amended
- Sep 9, 20268-KCurrent reportRegulation FD disclosure
- Aug 26, 2026S-1IPO registration
- Aug 17, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Other events
- Aug 13, 20268-KCurrent reportResults of operations
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Jul 24, 20268-KCurrent reportRegulation FD disclosure
- Jul 17, 20268-KCurrent reportListing notice
Official filings of Daré Bioscience, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $1 M
- Operating income
- $-14 M
- Net income
- $-13 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $32 M
- Total liabilities
- $30 M
- Total equity
- $3 M
As of December-2025
Top 37 institutional investors in Daré Bioscience, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 632,871 | -8,006 (-1.25%) | 4.14% | $1 M | Nov 13, 2026 |
| 2 | UBS Group AG | 239,597 | +232,787 (+3418.31%) | 1.57% | $0 M | Nov 10, 2026 |
| 3 | US Bancorp \de\ | 220,920 | +100,000 (+82.70%) | 1.44% | $0 M | Nov 5, 2026 |
| 4 | Geode Capital Management, LLC | 152,405 | +12,312 (+8.79%) | 1.00% | $0 M | Nov 6, 2026 |
| 5 | Vanguard Fiduciary Trust Co | 91,269 | 0 (0.00%) | 0.60% | $0 M | Nov 13, 2026 |
| 6 | BlackRock, Inc. | 62,162 | -2,086 (-3.25%) | 0.41% | $0 M | Nov 13, 2026 |
| 7 | State Street Corp | 47,415 | 0 (0.00%) | 0.31% | $0 M | Nov 12, 2026 |
| 8 | Citadel Advisors LLC | 45,142 | New | 0.30% | $0 M | Nov 16, 2026 |
| 9 | XTX Topco Ltd | 37,376 | New | 0.24% | $0 M | Nov 16, 2026 |
| 10 | HRT Financial LP | 37,342 | +14,912 (+66.48%) | 0.24% | $0 M | Nov 13, 2026 |
| 11 | Northern Trust Corp | 34,209 | 0 (0.00%) | 0.22% | $0 M | Nov 16, 2026 |
| 12 | Virtu Financial LLC | 33,506 | +17,703 (+112.02%) | 0.22% | $0 M | Nov 17, 2026 |
| 13 | Two Sigma Securities, LLC | 19,656 | New | 0.13% | $0 M | Nov 16, 2026 |
| 14 | Garde Capital, Inc. | 16,220 | New | 0.11% | $0 M | Oct 29, 2026 |
| 15 | LPL Financial LLC | 14,889 | 0 (0.00%) | 0.10% | $0 M | Nov 6, 2026 |
| 16 | Raymond James Financial Inc | 14,628 | -236 (-1.59%) | 0.10% | $0 M | Nov 12, 2026 |
| 17 | Price T Rowe Associates Inc /MD/ | 13,318 | 0 (0.00%) | 0.09% | $0 M | Nov 16, 2026 |
| 18 | Objectivity Squared, LLC | 10,915 | 0 (0.00%) | 0.07% | $0 M | Nov 12, 2026 |
| 19 | Farther Finance Advisors, LLC | 9,408 | -42 (-0.44%) | 0.06% | $0 M | Oct 8, 2026 |
| 20 | Vanguard Global Advisers, LLC | 2,940 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 21 | Tower Research Capital LLC (TRC) | 1,733 | New | 0.01% | $0 M | Nov 16, 2026 |
| 22 | PNC Financial Services Group, Inc. | 1,100 | New | 0.01% | $0 M | Nov 6, 2026 |
| 23 | IFS Advisors, LLC | 950 | 0 (0.00%) | 0.01% | $0 M | Oct 14, 2026 |
| 24 | SBI Securities Co., Ltd. | 715 | +70 (+10.85%) | 0.00% | $0 M | Oct 22, 2026 |
| 25 | Royal Bank Of Canada | 596 | New | 0.00% | $0 M | Nov 16, 2026 |
Show all 37: investors 26 to 37
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Entrust Financial LLC | 500 | New | 0.00% | $0 M | Nov 4, 2026 |
| 27 | Jacobi Capital Management LLC | 434 | New | 0.00% | $0 M | Nov 5, 2026 |
| 28 | Jones Financial Companies Lllp | 396 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 29 | Keating Financial Advisory Services, Inc. | 107 | New | 0.00% | $0 M | Nov 12, 2026 |
| 30 | Caldwell Sutter Capital, Inc. | 100 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 31 | Mather Group, LLC. | 84 | 0 (0.00%) | 0.00% | $0 M | Oct 14, 2026 |
| 32 | Jpmorgan Chase & Co | 19 | New | 0.00% | $0 M | Nov 12, 2026 |
| 33 | Inspire Investing, LLC | 14 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 34 | FMR LLC | 6 | New | 0.00% | $0 M | Nov 10, 2026 |
| 35 | Compass Financial Management LLC | 5 | New | 0.00% | $0 M | Oct 30, 2026 |
| 36 | Barclays PLC | 2 | -246 (-99.19%) | 0.00% | $0 M | Nov 6, 2026 |
| 37 | Putney Financial Group LLC | 1 | New | 0.00% | $0 M | Oct 30, 2026 |
Mutual funds holding Daré Bioscience, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 471,486 | $1 M | 3.1% | <0.01% | +90% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 161,385 | $0 M | 1.1% | <0.01% | −25% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 78,050 | $0 M | 0.51% | <0.01% | +6.3% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 45,289 | $0 M | 0.30% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 32,473 | $0 M | 0.21% | <0.01% | +149% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 15,326 | $0 M | 0.10% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 7,571 | $0 M | 0.05% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 8,006 | $0 M | 0.05% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 2,978 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 626 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Daré Bioscience, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Susan L. KelleyDirector | Grant or award | +23,696 | — | — | 23,696 | Form 4 |
| filed | Gregory W. MatzDirector | Grant or award | +30,805 | — | — | 30,847 | Form 4 |
| filed | William H. RastetterDirector | Grant or award | +38,862 | — | — | 39,721 | Form 4 |
| filed | Jessica D. GrossmanDirector | Grant or award | +26,066 | — | — | 26,066 | Form 4 |
| filed | Robin Joan SteeleDirector | Grant or award | +26,540 | — | — | 47,055 | Form 4 |
| filed | Roger HawleyDirector | Buyindirect | +454,545 | $1.100 | $500 K | 944,956 | Form 4 |
| filed | Roger HawleyDirector | Buy | +140,000 | $1.450 | $203 K | 140,000 | Form 4 |
| filed | Sabrina Martucci JohnsonChief Executive Officer, Director, 10% owner | Grant or awardindirect | +962,062 | — | — | 962,062 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Daré Bioscience, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-12 reverse split ; 1-for-10 reverse split in the period to ; 1-for-10 reverse split ; 14.507-for-1 split
Trading halts
- 2026-08-14 16:45 UTC, code LUDP, resumed 16:50 UTC
Fails to deliver
- : 2,356 shares at $0.66
- : 5,262 shares at $0.65
- : 12,798 shares at $0.69
- : 9,326 shares at $0.69
- : 314 shares at $0.73
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Daré Bioscience, Inc. scorecard#
Passes 2 of the 13 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 28, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median4.6×Price to book 4.6× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median12.6×Price to sales 12.6× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-79.2%Free cash flow is -79.2% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.20 vs -0.48Diluted EPS -1.20 in fiscal 2025 against -0.48 the year before (report's currency).
- ✓Net income higher than five years earlier-$13 M-$13 M in fiscal 2025 against -$27 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$13 MNet income -$13 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities1.1×Current ratio 1.14 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-9.09Z-score -9.09 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year31.6%Diluted shares up 31.6% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Daré Bioscience, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 1.0+10429%100% | 0.0−99.7%100% | 2.8−71.9%100% | 10—100% | 0—— | — | — | — | — | 0.8—100% | |
| Cost of revenue | 0.3—28.7% | 0—0.0% | — | — | — | — | — | — | — | — | |
| Research and development | 5.5−61.4%536% | 14r14−33.6%146210% | 22−28.3%767% | 30−1.9%300% | 31+47.4%— | 21+143%— | 8.5+33.2%— | 6.4+551%— | 1.0+1255%— | 0.1r28—9.5% | |
| Selling, general and administrative | 8.8−4.3%851% | 9.2—93582% | — | — | — | — | — | — | — | — | |
| General and administrative | — | 9.2−24.4%93582% | 12+7.7%431% | 11+34.6%112% | 8.4+27.5%— | 6.5+24.4%— | 5.3+13.1%— | 4.7+72.1%— | 2.7+1613%— | 0.2r10—20.6% | |
| Operating expenses | 14−39.1%1387% | 23−30.5%239792% | 34−18.5%1202% | 41+5.9%414% | 39+42.6%— | 27+91.0%— | 14−15.0%— | 17+51.0%— | 11+1673%— | 0.6r38—82.3% | |
| Operating income | −14—−1316% | −23—−239692% | −31—−1102% | −31—−314% | −39—— | −27—— | −14—— | −17—— | −11—— | −0.6—−82.3% | |
| Interest and finance income | — | — | — | — | — | — | — | — | — | 0.1—11.2% | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | 0.3+666%— | 0.0r2.2—5.5% | |
| Other non-operating income (expense) | −0.2−116%−14.9% | 1.0r−1.0+26.1%10032% | 0.8+77.8%27.7% | 0.4+17271%4.4% | 0.0+66.4%— | 0.0−98.1%— | 0.1−43.5%— | 0.1—— | −0.3—— | −2.2—−281% | |
| Income before tax | −14—−1314% | −4.1—−41415% | −30—−1074% | −31—−309% | −39—— | −27—— | −14—— | −17—— | −12—— | −0.7—−87.9% | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—— | 0—— | 0−100%— | 0.0—— | 0—— | — | |
| Net income attributable to shareholders | −13—−1301% | −4.1—−41431% | −30—−1074% | −31—−309% | −39—— | −27—— | −14—— | −17—— | −12—— | −0.7r−39—−87.8% | |
| Earnings per share, basic | -1.20—— | -0.48—— | -4.15r-0.35—— | -0.37—— | -0.63—— | -0.91—— | -0.97—— | -1.57r1.57−144%— | 3.56r-3.56—— | -0.81r-1.42—— | |
| Earnings per share, diluted | -1.20—— | -0.48—— | -4.15r-0.35—— | -0.37—— | -0.63—— | -0.91—— | -0.97—— | -1.57r1.57−144%— | 3.56r-3.56—— | -0.81r-1.42—— | |
| Shares, weighted average (basic) | 11+31.6%— | 8.5+16.8%— | 7.3r87−91.4%— | 85+38.3%— | 61+103%— | 30—— | — | — | 3.2+287%— | 0.8—— | |
| Shares, weighted average (diluted) | 11+31.6%— | 8.5+16.8%— | 7.3r87−91.4%— | 85+38.3%— | 61+103%— | 30+93.2%— | 16+45.2%— | 11+232%— | 3.2+287%— | 0.8r28—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 25+57.4%76.1% | 16+49.8%71.0% | 10−69.8%49.2% | 35−32.9%79.1% | 52+1007%92.6% | 4.7−2.3%61.8% | 4.8−29.8%64.2% | 6.8−10.0%86.9% | 7.6+16845%53.0% | 0.0r35—100% | |
| Receivables | — | — | — | — | 0—0.0% | — | — | — | — | 0.8—1845% | |
| Other current assets | 0.6—1.8% | 0—0.0% | 0—0.0% | 0—0.0% | — | — | — | 0−100%0.0% | 0.2−81.0%1.4% | 1.0—2280% | |
| Current assets | 27+46.7%83.3% | 18+5.2%83.5% | 18−59.2%82.4% | 43−22.2%98.2% | 55+692%99.1% | 7.0+8.4%92.5% | 6.4−11.0%86.6% | 7.2−13.3%92.5% | 8.3+18614%58.5% | 0.0r37—100% | |
| Property, plant and equipment | 1.6+16.7%4.8% | 1.3+104%6.0% | 0.7+911%3.1% | 0.1+149%0.1% | 0.0−31.3%0.0% | 0.0−40.3%0.5% | 0.1+576%0.9% | 0.0—0.1% | 0−100%0.0% | 0.7—1497% | |
| Right-of-use (leased) assets | 1.1−9.1%3.4% | 1.2−8.5%5.5% | 1.3+188%6.2% | 0.5r0.5—1.0% | — | — | — | — | — | — | |
| Goodwill | — | — | — | — | — | — | — | 0−100%0.0% | 5.2r5.2—36.5% | — | |
| Total assets | 32+46.9%100% | 22+3.8%100% | 21−51.4%100% | 44−21.5%100% | 56+639%100% | 7.6+1.5%100% | 7.4−4.9%100% | 7.8−45.1%100% | 14+31863%100% | 0.0r38—100% | |
| Accounts payable | 1.2−17.5%3.7% | 1.5−57.0%6.6% | 3.4+66.9%15.9% | 2.0−3.6%4.6% | 2.1+106%3.8% | 1.0−5.7%13.5% | 1.1+136%14.6% | 0.5+49.1%5.9% | 0.3r0.3−78.7%2.2% | 1.4—3241% | |
| Debt due within a year | — | 0.0r0—0.0% | — | — | — | — | — | — | — | — | |
| Current liabilities | 24+9.6%72.9% | 22r22+5.5%97.8% | 20−35.2%96.2% | 32+97.0%72.2% | 16+110%28.8% | 7.7+36.5%101% | 5.6+414%75.4% | 1.1+12.9%13.9% | 1.0+28.0%6.8% | 0.8r17—1693% | |
| Lease liabilities (non-current) | 0.6−25.9%1.7% | 0.8−19.4%3.4% | 0.9+936%4.4% | 0.1—0.2% | 0−100%0.0% | 0.0r0.0−89.3%0.6% | 0.4+0.1%5.2% | 0.4—5.0% | — | — | |
| Non-current liabilities | — | — | — | — | — | — | — | — | — | 7.6—17120% | |
| Total liabilities | 30+5.4%91.2% | 28+6.8%127% | 26−19.5%124% | 33+91.8%74.6% | 17+96.0%30.6% | 8.7+24.3%115% | 7.0+536%94.1% | 1.1+13.8%14.1% | 1.0+28.0%6.8% | 0.8—1693% | |
| Retained earnings | −189—−581% | −175—−793% | −171—−805% | −141—−322% | −110—−197% | −71—−946% | −44—−591% | −29—−370% | −12—−85.8% | −0.7r−201—−1631% | |
| Shareholders' equity | 2.8—8.8% | −6.0—−27.2% | −5.0−145%−23.7% | 11−71.3%25.4% | 39—69.4% | −1.2−361%−15.3% | 0.4−93.4%5.9% | 6.7−49.4%85.9% | 13r13—93.2% | −0.7r13—−1593% | |
| Total liabilities and equity | 32+46.9%100% | 22+3.8%100% | 21−51.4%100% | 44−21.5%100% | 56+639%100% | 7.6+1.5%100% | 7.4−4.9%100% | 7.8−45.1%100% | 14+31863%100% | 0.0r38—100% | |
| Shares outstanding | 14+66.7%— | 8.7+4.4%— | 8.3r100−90.2%— | 85+1.0%— | 84+102%— | 42+111%— | 20+72.3%— | 11+88.9%— | 6.0+565%— | 0.9r29—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 1.6+3762%159% | 0.0—433% | — | — | — | — | — | — | — | 0.3—34.1% | |
| Share-based compensation | 1.5−32.1%145% | 2.2−12.9%22519% | 2.5+17.2%90.1% | 2.2+34.9%21.6% | 1.6+116%— | 0.7+60.5%— | 0.5+232%— | 0.1+780%— | 0.0+75.7%— | 0.0r2.8—1.2% | |
| Cash from operating activities | −9.9−281%−960% | 5.5r5.4—55944% | −39—−1384% | −18—−181% | −29—— | −25—— | −13—— | −10—— | −2.5—— | −0.4r−34—−48.6% | |
| Capital expenditure | −0.4—−37.4% | −0.6—−5857% | −0.6—−22.4% | −0.1—−0.6% | −0.0—— | −0.0—— | 0—— | −0.0—— | 0—— | −0.5—−69.8% | |
| Cash from investing activities | −0.4—−37.4% | −0.6—−5857% | −0.6—−22.4% | −0.1—−0.6% | −0.0—— | −0.0−100%— | 6.1—— | −0.5−105%— | 9.9—— | −0.4—−54.6% | |
| Shares issued | 21+4514%2032% | 0.5—4636% | — | 1.3−92.0%13.0% | 16−29.1%— | 23+346%— | 5.2—— | — | — | 0.9—120% | |
| Cash from financing activities | 19+5338%1871% | 0.4r0.4−97.7%3623% | 16+1064%557% | 1.3−98.2%13.4% | 76+202%— | 25+388%— | 5.2−49.1%— | 10+6424%— | 0.2−21.5%— | 0.2r−7.0—25.8% | |
| Exchange-rate effect on cash | 0.0—0.7% | −0.1—−694% | −0.0—−0.3% | −0.2—−2.0% | −0.1−666%— | 0.0—— | −0.0—— | −0.1—— | — | — | |
| Change in cash | 9.0+73.8%875% | 5.2r5.2—53016% | −24—−850% | −17−136%−170% | 47—— | −0.1—— | −2.0—— | −0.8−110%— | 7.5—— | −0.2r−41—−22.8% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 1.4—100% | 0.2—100% | 0.2+500%100% | 1.0*—100% | 0.0−94.6%100% | — | 0.0+173%100% | — | 0.0−95.8%100% | 0.0—100% | 0.0—100% | 1.8*—100% | 1.0—100% | |
| Cost of revenue | — | 0.3—171% | 0.2—159% | — | — | 0—— | 0—0.0% | — | — | — | — | — | — | |
| Research and development | 2.7−72.3%198% | 0.2−83.1%129% | 0.7−71.3%433% | 0.6*−81.4%60.8% | 1.2−56.2%51953% | 1.4−71.0%— | 2.3−31.5%9035% | 3.3r3.3*−12.2%— | 2.7r2.7−59.8%6432% | 4.9r4.9—21988% | 3.4r3.3—36052% | 3.8*—210% | 6.7—667% | |
| Selling, general and administrative | — | 2.6+9.1%1383% | 2.2−2.6%1475% | — | — | 2.4—— | 2.3—9082% | — | — | — | — | — | — | |
| General and administrative | — | — | — | — | 2.5+22.4%110488% | 2.4−2.9%— | 2.3−13.5%9082% | 2.0*−36.7%— | 2.0−24.3%4896% | 2.4—10911% | 2.7—28710% | 3.2*—175% | 2.7—270% | |
| Operating expenses | 12−37.1%851% | 2.8−25.5%1512% | 2.9−36.9%1908% | 2.2*−58.7%215% | 3.7−22.2%162441% | 3.8−48.4%— | 4.6−23.6%18117% | 5.3*−23.7%— | 4.7−49.7%11329% | 7.4—32899% | 6.0—64844% | 7.0*—386% | 9.4—940% | |
| Operating income | −11—−813% | −3.0—−1583% | −3.0—−1967% | −1.5*—−144% | −3.7—−162341% | −3.8—— | −4.6—−18017% | −5.4*—— | −4.7—−11229% | −7.4—−32799% | −6.0—−64744% | −5.2*—−286% | −8.4—−840% | |
| Other non-operating income (expense) | −0.2−110%−13.4% | −0.0—−7.9% | −0.0−100%−0.7% | −0.3*−115%−27.0% | 0.1—4836% | −0.2—— | 0.2—798% | 1.8r−0.1*+1520%— | −0.0−122%−50.7% | −0.1—−487% | −0.7—−7879% | 0.1*—6.3% | 0.1—9.7% | |
| Net income attributable to shareholders | −11—−804% | −3.0—−1590% | −3.0—−1968% | −1.4*—−141% | −3.6—−157505% | −4.0−131%— | −4.4—−17219% | −5.5*—— | −4.7—−11279% | 13—57539% | −6.8—−72623% | −5.1*—−280% | −8.3—−830% | |
| Earnings per share, basic | — | -0.20—— | -0.21—— | — | -0.28—— | -0.45−129%— | -0.50—— | — | -0.55—— | 1.53—— | -0.81r-0.07—— | — | -1.09r-0.09—— | |
| Earnings per share, diluted | — | -0.20—— | -0.21—— | — | -0.28—— | -0.45−130%— | -0.50—— | — | -0.55—— | 1.52—— | -0.81r-0.07—— | — | -1.09r-0.09—— | |
| Shares, weighted average (basic) | 15+67.8%— | 15+67.8%— | 15+65.8%— | — | 13+49.5%— | 8.9+5.5%— | 8.8+4.6%— | — | 8.5+12.5%— | 8.4—— | 8.4r101—— | — | 7.6r91—— | |
| Shares, weighted average (diluted) | 15+67.8%— | 15+67.8%— | 15+65.8%— | — | 13+49.5%— | 8.9+4.7%— | 8.8+4.6%— | — | 8.5+12.5%— | 8.5—— | 8.4r101—— | — | 7.6r91—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 13—56.4% | 13+151%56.4% | 19+79.3%66.5% | 25+57.4%76.1% | 23+105%75.0% | 5.0−69.3%38.8% | 10+185%55.5% | 16+49.8%71.0% | 11−19.2%62.2% | 16—69.5% | 3.6—27.9% | 10—49.2% | 14—55.5% | |
| Other current assets | 0.5—2.0% | 0.5—2.0% | 0.7—2.5% | 0.6—1.8% | 0.1—0.2% | — | — | 0—0.0% | — | — | 0.2—1.2% | 0—0.0% | 0.8—3.3% | |
| Current assets | 17—74.6% | 17+153%74.6% | 22+83.2%77.8% | 27+46.7%83.3% | 25+67.3%81.3% | 6.6−68.3%50.9% | 12+18.4%63.5% | 18+5.2%83.5% | 15−33.4%82.8% | 21—88.2% | 10.0—76.7% | 18—82.4% | 22—89.5% | |
| Property, plant and equipment | 1.4—6.3% | 1.4−14.0%6.3% | 1.4−2.4%5.2% | 1.6+16.7%4.8% | 1.7+135%5.4% | 1.7+412%12.7% | 1.5+2729%8.0% | 1.3+104%6.0% | 0.7+1105%3.9% | 0.3—1.4% | 0.1—0.4% | 0.7—3.1% | 0.1—0.2% | |
| Right-of-use (leased) assets | 0.8—3.7% | 0.8−12.4%3.7% | 1.0−10.5%3.5% | 1.1−9.1%3.4% | 0.8−37.9%2.7% | 1.0−33.9%7.4% | 1.1−30.6%5.8% | 1.2−8.5%5.5% | 1.3+630%7.4% | 1.4—6.1% | 1.6—12.0% | 1.3—6.2% | 0.2—0.7% | |
| Total assets | 22—100% | 22+72.3%100% | 28+49.5%100% | 32+46.9%100% | 31+70.3%100% | 13−45.0%100% | 19+43.1%100% | 22+3.8%100% | 18−27.9%100% | 24—100% | 13—100% | 21—100% | 25—100% | |
| Accounts payable | 0.8—3.4% | 0.8−56.7%3.4% | 1.2−34.6%4.4% | 1.2−17.5%3.7% | 1.8+75.9%6.0% | 1.8−7.7%13.6% | 1.9−53.4%10.1% | 1.5−57.0%6.6% | 1.0−79.0%5.8% | 1.9—8.1% | 4.0—31.1% | 3.4—15.9% | 5.0—19.9% | |
| Debt due within a year | — | — | — | — | 0.0—0.0% | 0.2—1.4% | 0.1—0.5% | 0.0r0—0.0% | — | — | — | — | — | |
| Current liabilities | 17—75.6% | 17−12.0%75.6% | 21−0.3%75.9% | 24+9.6%72.9% | 21+61.3%69.0% | 19+31.7%148% | 21+19.5%114% | 22r22+5.5%97.8% | 13−50.1%72.8% | 15—61.8% | 18—136% | 20—96.2% | 26—105% | |
| Lease liabilities (non-current) | 0.3—1.2% | 0.3−38.9%1.2% | 0.4−30.7%1.5% | 0.6−25.9%1.7% | 0.3−67.9%0.9% | 0.4−56.8%3.5% | 0.6−48.5%3.2% | 0.8−19.4%3.4% | 0.9—5.0% | 1.0—4.4% | 1.2—9.0% | 0.9—4.4% | 0—0.0% | |
| Total liabilities | 23—103% | 23−10.8%103% | 27−3.9%97.4% | 30+5.4%91.2% | 28+42.7%90.7% | 26+22.8%198% | 28+17.4%151% | 28+6.8%127% | 20−28.5%108% | 21—88.7% | 24—185% | 26—124% | 27—109% | |
| Retained earnings | −195—−870% | −195—−870% | −192—−689% | −189—−581% | −187—−609% | −184—−1415% | −180—−965% | −175—−793% | −170—−940% | −165—−699% | −178—−1368% | −171—−805% | −166—−663% | |
| Shareholders' equity | −0.6—−2.5% | −0.6—−2.5% | 0.7—2.6% | 2.8—8.8% | 2.9—9.3% | −13−577%−98.1% | −9.6—−51.4% | −6.0—−27.2% | −1.5—−8.2% | 2.7—11.3% | −11—−84.5% | −5.0—−23.7% | −2.3—−9.1% | |
| Total liabilities and equity | 22—100% | 22+72.3%100% | 28+49.5%100% | 32+46.9%100% | 31+70.3%100% | 13−45.0%100% | 19+43.1%100% | 22+3.8%100% | 18−27.9%100% | 24—100% | 13—100% | 21—100% | 25—100% | |
| Shares outstanding | 15—— | 15+68.0%— | 15+64.5%— | 14+66.7%— | 14+63.0%— | 9.0+5.7%— | 8.9−91.2%— | 8.7+4.4%— | 8.5−91.3%— | 8.5—— | 101—— | 8.3r100—— | 98—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 2.1+230%156% | 0.6*+26.0%305% | 0.6+216%364% | 0.5*+8292%52.2% | 0.5r0.5*+4727%20791% | 0.5r0.5*+2842%— | 0.2r0.2+1530%691% | 0.0*—— | 0.0*—23.4% | 0.0*—68.8% | 0.0—116% | — | — | |
| Share-based compensation | 1.5−14.1%110% | 0.3−20.2%153% | 0.5+20.6%298% | 0.4*−27.0%34.9% | 0.4*−23.0%17817% | 0.4−36.2%— | 0.4−39.9%1484% | 0.5*−21.1%— | 0.5*−17.7%1256% | 0.6*—2508% | 0.6—6748% | 0.6*—34.3% | 0.6*—63.6% | |
| Cash from operating activities | −11—−827% | −6.8*—−3612% | −5.5—−3621% | 1.4*−72.8%141% | −0.4*—−19546% | −5.4*−142%— | −5.5—−21515% | 5.3r5.2*—— | −5.9*—−14210% | 13*—57513% | −6.8—−73242% | −8.2*—−452% | −8.0*—−797% | |
| Capital expenditure | −0.5—−33.8% | −0.1*—−43.0% | 0—0.0% | −0.2*—−20.2% | −0.2*—−7723% | — | −0.2—−619% | −0.6*—— | — | −0.3*—−1271% | −0.0—−78.4% | −0.6*—−33.6% | −0.0*—−2.2% | |
| Cash from investing activities | −0.5—−33.8% | −0.1*−153%−43.0% | 0—0.0% | −0.2*—−20.2% | −0.2*−162%−7723% | 0.2*—— | −0.2—−619% | −0.6*—— | 0.3*—677% | −0.3*—−1271% | −0.0—−78.4% | −0.6*—−33.6% | −0.0*—−2.2% | |
| Shares issued | — | 0.2*−64.9%88.9% | 0.1−78.2%62.2% | — | — | 0.5*—— | 0.4—1716% | — | — | — | — | — | — | |
| Cash from financing activities | 19+4413%1414% | 1.0*—507% | −0.7−390%−469% | 0.4*—41.4% | 19*+4173%824502% | −0.0*−138%— | 0.2+1657%970% | −0.2r−0.1*−104%— | 0.4*−94.9%1047% | 0.1*—514% | 0.0—151% | 5.3*—294% | 8.6*—858% | |
| Exchange-rate effect on cash | 0.0—2.0% | 0.0*−82.7%1.2% | 0.0+240%29.2% | −0.0*—−2.5% | 0.0*−70.1%303% | 0.0*−11.5%— | 0.0—51.5% | −0.1*−213%— | 0.0*—55.0% | 0.0*—64.9% | −0.0—−422% | 0.1*—3.2% | −0.0*—−1.5% | |
| Change in cash | 7.6—555% | −5.9*—−3147% | −6.2—−4061% | 1.6*−63.4%160% | 18*—797536% | −5.3*−142%— | −5.4—−21112% | 4.5r4.5*—— | −5.2*−1017%−12430% | 13*—56821% | −6.8—−73591% | −3.4*—−189% | 0.6*—56.5% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Daré Bioscience, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- License fee revenue and other revenue$1 M100%+10200%
Business segments
- Reportable$1 M100%+10200%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where Daré Bioscience, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 4 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office3 subsidiaries | — |
| 🇦🇺 Australia | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Events at Daré Bioscience, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 2 · Directors and officers 2 · Material agreement 1 · Agreement ended 1 · Unregistered share sale 8 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 5
| Filed | What happened | Filing |
|---|---|---|
| Shareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Unregistered share sale | 8-K | |
| Results announced | 8-K | |
| Unregistered share sale | 8-K | |
| Unregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Unregistered share sale | 8-K | |
| Results announced | 8-K | |
| Unregistered share sale | 8-K | |
| Unregistered share sale | 8-K | |
| Unregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Agreement ended | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
6 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2026 | $12 M | Private placement after listing | $10 to $50 million | 12 | options | SEC |
| Dec 2023 | $2 M | Private placement after listing | Under $2 million | 1 | options | SEC |
| Nov 2019 | $4 M | Private placement after listing | $2 to $10 million | 28 | equity | SEC |
| Jul 2017 | $21 M | Private placement after listing | $10 to $50 million | 18 | equity, options | SEC |
| Nov 2012 | $13 M | No. 6 | $10 to $50 million | 16 | equity | SEC |
| Dec 2011 | $15 M | No. 5 | $10 to $50 million | 19 | equity, options | SEC |
| Nov 2010 | $17 M | No. 4 | $10 to $50 million | 17 | equity | SEC |
| Sep 2010 | $2 M | No. 3 | Under $2 million | 15 | debt, options | SEC |
| May 2010 | $5 M | No. 2 | $2 to $10 million | 13 | debt, options | SEC |
| Jul 2009 | $10 M | No. 1 | $10 to $50 million | 13 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Government contracts: Daré Bioscience, Inc.#
No federal contracts in fiscal 2025, and $2.0 M in grants.
| Fiscal year | Contracts | Grants |
|---|---|---|
| FY2025 | $0 | $2.0 M |
| FY2024 | $0 | $960 K |
| FY2023 | $0 | $385 K |
| FY2021 | $0 | $310 K |
Source: USAspending.gov. Obligations are binding promises to pay, not payments, and can be negative when an award is cut. Counted under Daré Bioscience, Inc.: DARE BIOSCIENCE, INC. (UEI UC4EFLZHANH4)
H-1B hiring at Daré Bioscience, Inc.#
1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $99 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior AccountantAccountants and Auditors | 1 | $99 K |
Where: San Diego, CA 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Dare Bioscience, Inc.
How Daré Bioscience, Inc. compares in Biotechnology
- Market cap$13 M · higher than 13% of 726
- Revenue$1 M · higher than 25% of 647
- Price / sales12.6× · lower than 38% of 339
- Price / book4.6× · lower than 33% of 534
- FCF yield-79.2% · higher than 13% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Daré Bioscience, Inc.🇺🇸 | $13 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 28, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 25, 2026
- Profile updated:
- Nov 19, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Daré Bioscience, Inc.? Verify and update this profile — free
Show Daré Bioscience, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.